Although some animal studies have suggested the therapeutic potential of FGF-19 and FGF-21 in the treatment of obesity, diabetes or metabolic syndrome [6], still little is known about their role in the metabolic disorders. The gene discussed is FGF19; the disease is obesity due to melanocortin 4 receptor deficiency.